Therapy For Xenograft Human Pancreatic Cancer In Mice Medicated By Apoptin Gene

BackgroundAfter2000, with the rapid development of the global economy, human life hadimproved continuously, the life customs and the diet has changed a lot, the human diseasespectrum has also undergone a change, cancer become a major killer which threat tohuman health. In recent years, in all of the humans suffering from cancer, the proportion ofpancreatic cancer is growing.The Statistics show that in2009the United States added42,470cases of pancreatic cancer patients, the death of35,240cases, the fatality rate isapproximately equal to the incidence of patients, the5-year survival rate is less than5%[1].In recent years, although the surgical technology and the medical equipment haveimproved a lot which have promoted resection of pancreatic cancer improved the rate ofdiagnosis of pancreatic cancer and rate of pancreatic cancer resection, the rate ofperioperative mortality and complications are greatly declined, but the treatment effect hasno significant improved and the overall5-year survival is still less than5%.In recent years, the molecular biology techniques has a rapid development. Thehumans have a whole understanding for the tumor pathogenesis and the mechanism. It isfound that cancer treatment can be achieved by inducing apoptosis. Therefore, it is animportant step to find and to develop the pro-apoptotic factors in the cancer treatmentprogram. It was found that a small molecule protein which is named Apoptin has a goodvalue.Apoptin is the function protein of the Chicken Anemia Virus(CAV). It canspecifically induce tumor and transformed cells to apoptosis, but it is no effect on normaland non-ransformed cells.It is different from other apoptosis factors because its inductionof apoptosis does not depend on the tumor suppressor gene p53, from the proto-oncogenebcl-2inhibition, on the contrary, overexpression of bcl-2to its there to promote therole.Apoptin is expected to become a new kind of anti-tumor agents.ObjectiveThrough the establishment of human pancreatic cancer nude mice xenograft model to observe the study the plasmid containing the apoptin gene on human pancreatic cancernude mouse subcutaneous tumor growth inhibition, to provide a theoretical basis for genetherapy of pancreatic cancer.MethodsEstablished nude mouse human pancreatic tumor transplantation tumor model byinjecting PANC-1cells subcutaneously; To observe the growth of nude mousetransplantation tumor when tumor diameter was about5mm, using the liposomemethod,pEGFP-Apoptin plasmid injected in the local of the tumor, pEGFP-C2plasmidgroup and physiological saline group were established as control groups, Observed thegrowth of nude mouse transplantation tumor and the growth of nude mouse. The mice werekilled five weeks later, take the tumor tissue embedded in paraffin and conventional slices,HE staining, by TUNEL apoptosis detection kit transplanted tumor apoptosis.ResultsEstablished nude mouse exnograft tumor model sucessfully, the size of the pEGFP-Apoptin treatment group transplanted subcutaneously in nude mouse is different from thepEGFP-C2plasmid group and physiological saline group. The histological resultsdemonstrated that the Apoptin can inhibit the growth of tumor by inducing the apoptosis ofthe Pancreatic cancer cells.ConclusionApoptin could significantly inhibit panceratic cancer cell growth. Apoptin could inhibitobviously the growth of nude mouse human Pancreatic carcinoma transplantation tumor byinducing apoptosis.